Consequences and costs of NSAID-gastropathy in Germany;Konsequenzen und kosten der NSA-gastropathie in Deutschland

Aktuelle Rheumatologie

Volumn 24, Issue 5, 1999, Pages 127-134

  Bolten, Wolfgang W ^a,e   Lang, B ^b   Wagner, A V ^c   Krobot, K J ^d  

^a Rheumaklinik Wiesbaden   (Germany)

^b Krpankhs fur Inn Med/Rheumatol   (Germany)

^c Statistical Department   (Germany)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIEMETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROKINETIC AGENT; PROTON PUMP INHIBITOR; SPASMOLYTIC AGENT;

ARTICLE; CLINICAL PROTOCOL; GERMANY; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; PEPTIC ULCER; REIMBURSEMENT;

EID: 0033392229     PISSN: 0341051X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1043560     Document Type: Article

References (39)

1. DPM Der Pharmazeutische Markt Deutschland. Statistik über den Apothekenumsatz pharmazeutischer Spezialitäten. IMS Health GmbH, Institut für Medizinische Statistik (Hrsg. und Verlag), Frankfurt: 1999
2. Gesundheitsbericht für Deutschland. Gesundheitsberichterstattung des Bundes/Statistisches Bundesamt, Wiesbaden (Hrsg). Stuttgart: Metzler-Poeschel, 1998: 194-199
3. Langman MJ. Ulcer complications and nonsteroidal anti-inflammatory drugs. Amer J Med 1988; 84 (2A): 15-19
4. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Amer J Gastroenterol 1987; 82 (11): 1153-1158
5. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs. New Engl J Med 1999; 340 (24): 1888-1899
6. O'Neill RT. Assessment of safety. Chapter 13. In: Peace, K (Hrsg). Biopharmaceutical Statistics for Drug Development. New York: Marcel Dekker, 1998: 543-604
7. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28 (5): 527-532
8. VIP Verschreibungsindex für Pharmazeutika Deutschland - Statistik über Therapie und Diagnosen niedergelassener Ärzte. IMS Health GmbH, Institut für Medizinische Statistik (Hrsg. und Verlag), Frankfurt: 1999
9. The Anatomical Classification of Pharmaceutical Products, http:// www.ephmra.org/zuletzt besucht am 12. März 1999
10. DDD (Defined Daily Dose) for pharmaceuticals and vitamins. Beziehbar über: WHO Collaborating Centre for Drug Statistics Methodology. P.O. Box 100 Veitvet, N-0518 Oslo 5, Norway, Fax: (+4722)169818
11. Schwabe U, Pfaffrath D. Arzneiverordnungsreport 1998. Berlin, Heidelberg: Springer, 1999
12. Rodriguez LAG, Walker AM, Gutthann SP. Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: A cohort study. Epidemiology 1992; 3 (4): 337-342
13. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115 (10): 787-796
14. Blower AL, Brooks A, Fenn GC, Hill A, Pearce MY, Morant S, Bardhan KD. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997; 11 (2): 283-291
15. Die private Krankenversicherung. Zahlenbericht 1997/98. Verband der privaten Krankenversicherungen e.V. (Hrsg). ISSN 0503-8839. http://www.pkv.de/brosch/brosch frame.htm zuletzt besucht am 29. Juli 1999
16. Rahme E, Kong SX, Watson DJ, LeLorier J. Use of concomittant gastro-protective agents, diagnostic testes, and hospitalization among elderly patients who started nonsteroidal antiinflammatory drugs in Quebec. Arth Rheum 1998; 41 (Suppl 9): S77
17. Moore N, Montout C, Verschuren X, Callens J, Kong SX, Begaud B. Use of gastrointestinal protective agents among patients on nonsteroidal antiinflammatory drugs in France and prevention or treatment of adverse GI effects. 12th EULAR Congress. June 6-11, 1999. Glasgow, Scotland: Rheumatol Europe, 1999
18. Langman M, Kahler KH, Kong SX, Finch E, Bentkover JD. Use of gastrointestinal protective agents and other healthcare resources among patients on non-steroidal antiinflammatory drugs in the United Kingdom. 12th EULAR Congress. June 6-11. Glasgow, Scotland: Rheumatol Europe, 1999
19. Koch M, Dezi A, Ferrario F, Capurso I. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 1996; 156 (20): 2321-2332
20. BolteN W W. Kapitel 5.1.2 Prophylaxe und Therapie von gastrointestinalen NSA-Nebenwirkungen. In: Deutsche Gesellschaft für Rheumatologie, Kornmission für Qualitätssicherung (Hrsg). Qualitätssicherung in der Rheumatologie. Darmstadt: Steinkopff, 1995: ISBN 3-7985-1012-1
21. Blum AL, Bolten WW, Labenz J, Stolte M, Rösch W. Therapie und PrÄvention des ASS-und NSAR-Ulkus. Dtsch Ärztebl 1998; 95 (7): A348-A354
22. Gabriel SE, Campion ME, O'Fallon WM. Patient preferences for nonsteroidal antiinflammatory drug related gastrointestinal complications and their prophylaxis. J Rheumatol 1993; 20 (2): 358-361
23. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123 (4): 241-249
24. Fachserie 12, Reihe 6.2. Diagnosedaten der Krankenhauspatien-ten, Band 1996, Statistisches Jahrbuch für die Bundesrepublik Deutschland. Statistisches Bundesamt. Wiesbaden: 1996
25. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P. Prophylactic aspirin and risk of peptic ulcer bleeding. Brit Med J 1995; 310 (6983): 827-830
26. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996; 156 (14): 1530-1536
27. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Amer J Med 1998; 105 (1B): 31 S-38 S
28. Masson J, Bramley P, Herd K. Prior use of Aspirin, NSAIDs and ulcer healing drugs in upper gastrointestinal bleeding presenting to an open access endoscopy unit. Gut 1993; 34 (4): S 39
29. Todesursachen in Deutschland 1997, Fachserie 12, Reihe 4. Statistisches Bundesamt, Wiesbaden (Hrsg). Stuttgart: Metzler-Poeschel, 1998
30. Moore RA, Phillips CJ. Cost of NSAID adverse effects to the UK National Health Service. J Medical Economics 1999; 2: 45-55
31. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 28: 6-10
32. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, Murphy M, Vessey MP, Colin-Jones DG. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343 (8905): 1075-1078
33. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Adverse Upper Gastrointestinal Effects of Rofecoxib Compared with NSAIDS. JAMA 1999; 282 (20): 1929-1933
34. Bjarnason I, Sigthorsson G, Crane R, Simon T, Hoover M, Bologne-se J et al. Cox-2 specific inhibition with MK-0966 25 or 50 mg QD does not increase intestinal permeability: A controlled study with placebo and indometacin 50 mg TID. Amer J Gastroenterol 1998; 93 (9): 1670
35. Hunt R, Bowen B, James C, Sridhar S, Simon T, Mortensen E et al. Cox-2 specific inhibition with MK-0966 25 or 50 mg QD over 4 weeks does not increase fecal blood loss. A controlled study with placebo and ibuprofen 800mg TID. Amer J Gastroenterol 1998; 93 (9): 1671
36. Lanza F, Simon T, Quan H, Bolognese J, Rack MF, Hoover M et al. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 250 mg QD is associated with less gastroduodenal damage than aspirin 650 mg QID or ibuprofen 800 mg (TID). Gastroenterology 1998; 112 (4): A194
37. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, Stern S, Quan H, Bolognese J, for the Rofecoxib Osteoarthritis Endoscopy Study Group. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117; 776-783
38. Laine L, Hawkey C, Harper S, Mortensen E, Beaulieu A, Quan H, Bolognese J, Simon T. Effect of the COX-2 specific inhibitor (C-2SI) rofecoxib on ulcer formation: A double-blind comparison with ibuprofen and placebo. Gastroenterology 1999; 116 (4): A229
39. Geis GS, Hubbared R, Callison D, Yu S, Zhao W. Safety and Efficacy of Celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Amer J Gastroenterol 1998; 93 (9): 1990